Buy Unlisted Shares & Get a ₹ 500 Amazon Voucher*
DRHP Status : Not Filed
P&L Statement | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Revenue | 242 | 359 | 419 | 396 |
Cost of Material Consumed | 70 | 102 | 112 | 111 |
Gross Margins | 71.07 | 71.59 | 73.27 | 71.97 |
Change in Inventory | -1 | -2 | -2 | 2 |
Employee Benefit Expenses | 61 | 63 | 64 | 75 |
Other Expenses | 80 | 113 | 143 | 135 |
EBITDA | 32 | 83 | 102 | 73 |
OPM | 13.22 | 23.12 | 24.34 | 18.43 |
Other Income | 2 | 3 | 5 | 7 |
Finance Cost | 4 | 2 | 2 | 1 |
D&A | 20 | 22 | 23 | 24 |
EBIT | 12 | 61 | 79 | 49 |
EBIT Margins | 4.96 | 16.99 | 18.85 | 12.37 |
PBT | 10 | 62 | 82 | 55 |
PBT Margins | 4.13 | 17.27 | 19.57 | 13.89 |
Tax | 2 | 18 | 25 | 11 |
PAT | 8 | 44 | 57 | 44 |
NPM | 3.31 | 12.26 | 13.6 | 11.11 |
EPS | 0.8 | 4.4 | 5.7 | 4.4 |
Financial Ratios |
2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Operating Profit Margin | 13.22 | 23.12 | 24.34 | 18.43 |
Net Profit Margin | 3.31 | 12.26 | 13.6 | 11.11 |
Earning Per Share (Diluted) | 0.8 | 4.4 | 5.7 | 4.4 |
Assets | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Fixed Assets | 337 | 340 | 328 | 347 |
CWIP | 2 | 0 | 5 | 2 |
Investments | 0 | 0 | 0 | 0 |
Trade Receivables | 18 | 20 | 20 | 27 |
Inventory | 9 | 11 | 13 | 11 |
Other Assets | 61 | 93 | 134 | 121 |
Total Assets | 427 | 464 | 500 | 508 |
Liabilities | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Share Capital | 100 | 100 | 100 | 100 |
FV | 10 | 10 | 10 | 10 |
Reserves | 195 | 231 | 273 | 300 |
Borrowings | 38 | 19 | 13 | 0 |
Trade Payables | 32 | 33 | 34 | 33 |
Other Liabilities | 62 | 81 | 80 | 75 |
Total Liabilities | 427 | 464 | 500 | 508 |
Name | Holding |
---|---|
Dr. Shamsheer Vayalil Parambath | 42.60% |
Mr. Yusuff Ali M A | 18.80% |
Other Investors | 38.58% |
Lakeshore Hospital & Research Centre Limited, a public, non-government company, is a leading multi-specialty hospital in Kerala, known for medical education, research, and patient-centered care, with its unlisted shares traded privately.
Strengths:
Consistent Financial Performance: In FY2023, the hospital reported a total operating income of ₹358.47 crore, a 17% increase from the previous year. The Profit Before Interest, Lease, Depreciation, and Tax (PBILDT) margin also improved to 24.43% from 22.88% in FY2022, indicating enhanced operational efficiency.
Experienced Medical Team: The hospital employs 207 specialist doctors as full-time consultants, ensuring a high standard of medical care and a broad range of specialties.
Diverse Medical Services: Offering services such as wireless capsule endoscopy, endoscopic ultrasonography, and double balloon enteroscopy, along with various organ transplantations, positions the hospital as a comprehensive healthcare provider in the region.
Improved Liquidity Position: The current ratio, measuring the ability to cover short-term liabilities with short-term assets, improved from 1.19 in 2022 to 1.76 in 2023, suggesting better liquidity management.
Weaknesses:
Dependence on Key Personnel: The hospital's reliance on its team of specialist doctors means that the departure of key medical staff could impact service delivery and patient trust.
Market Competition: The healthcare sector in India is highly competitive, with numerous hospitals offering similar services. Maintaining and enhancing patient inflow amidst such competition requires continuous investment in technology and quality care.
Regulatory Challenges: As with any healthcare institution, the hospital must navigate complex regulatory environments, which can impact operations and financial performance.
Liquidity Risk in Unlisted Shares: Investing in unlisted shares carries liquidity risks, as these shares are not traded on public stock exchanges, making it potentially challenging to find buyers when one wishes to sell.